Overview Dividends

(TEVA) Teva Pharma Industries - Ratings and Ratios

Exchange: NYSE • Country: Israel • Currency: USD • Type: Common Stock • ISIN: US8816242098

Generic Drugs, CNS Therapies, Respiratory Inhalers, Oncology Injections, OTC Creams

TEVA EPS (Earnings per Share)

EPS Growth (3Y CAGR): 3.48%
EPS Trend (3Y Correlation): -3.2%

TEVA Revenue

Revenue Growth (3Y CAGR): 5.33%
Revenue Trend (3Y Correlation): 61.7%

Risk via 10d forecast
Volatility	40.3%
Value at Risk 5%th	54.6%
Relative Tail Risk	-17.61%

Reward TTM
Sharpe Ratio	0.94
Alpha	35.82

Character TTM
Hurst Exponent	0.589
Beta	0.872
Beta Downside	0.979

Drawdowns 3y
Max DD	43.70%
Mean DD	14.30%
Median DD	12.06%

Description: TEVA Teva Pharma Industries October 14, 2025

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a global generic-drug leader that also markets a range of branded specialty medicines. Its product slate spans tablets, capsules, injectables, inhalers, transdermal patches, and combination devices, with a strategic focus on central nervous system, respiratory, and oncology therapies. In addition to manufacturing active pharmaceutical ingredients (APIs) and offering contract-manufacturing services, Teva runs an out-licensing platform that monetizes its extensive product portfolio.

Key branded assets include COPAXONE for multiple sclerosis, AJOVY (migraine prevention), UZEDY (schizophrenia), and oncology injectables BENDEKA and TREANDA. The company also sells OTC products under brands such as SUDOCREM and FLEGAMINA, and maintains collaborations with partners like Sanofi, Alvotech, and MedinCell to augment its pipeline and distribution reach.

As of FY 2023, Teva reported revenue of roughly $13.5 billion, with a net debt-to-EBITDA ratio of ≈ 3.2, reflecting ongoing balance-sheet deleveraging. The generic market is pressured by US pricing reforms and biosimilar competition, but growth in specialty injectables and the CNS segment offers a higher-margin offset. Assuming the company can sustain its 2024-2025 pipeline launches and maintain cost-discipline, the upside potential hinges on market share gains in the respiratory inhaler space and successful commercialization of its oncology injectables. For a deeper quantitative assessment, you may find the analytics on ValueRay useful for benchmarking TEVA’s valuation against sector peers.

TEVA Stock Overview

Market Cap in USD	30,241m
Sub-Industry	Pharmaceuticals
IPO / Inception	1990-03-26
Return 12m vs S&P 500	33.3%
Analyst Rating	4.45 of 5

TEVA Dividends

Currently no dividends paid

TEVA Growth Ratios

CAGR 3y	43.31%
CAGR/Max DD Calmar Ratio	0.99
CAGR/Mean DD Pain Ratio	3.03
Current Volume	10071.1k
Average Volume	10630.1k

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (712.0m TTM) > 0 and > 6% of Revenue (6% = 1.01b TTM)

FCFTA 0.01 (>2.0%) and ΔFCFTA -3.29pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 7.42% (prev -8.84%; Δ 16.26pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.03 (>3.0%) and CFO 1.07b > Net Income 712.0m (YES >=105%, WARN >=100%)

Net Debt (14.89b) to EBITDA (3.69b) ratio: 4.04 <= 3.0 (WARN <= 3.5)

Current Ratio 1.11 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (1.16b) change vs 12m ago 2.74% (target <= -2.0% for YES)

Gross Margin 50.09% (prev 49.88%; Δ 0.21pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 41.11% (prev 40.19%; Δ 0.92pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 1.80 (EBITDA TTM 3.69b / Interest Expense TTM 1.49b) >= 6 (WARN >= 3)

Altman Z'' -1.06

(A) 0.03 = (Total Current Assets 12.74b - Total Current Liabilities 11.49b) / Total Assets 39.86b

(B) -0.36 = Retained Earnings (Balance) -14.24b / Total Assets 39.86b

(D) -0.51 = Book Value of Equity -16.66b / Total Liabilities 32.60b

Total Rating: -1.06 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 52.38

1. Piotroski 1.0pt = -4.0

2. FCF Yield 1.28% = 0.64

3. FCF Margin 3.45% = 0.86

4. Debt/Equity 2.36 = 0.22

5. Debt/Ebitda 4.04 = -2.50

6. ROIC - WACC (= 1.41)% = 1.77

7. RoE 11.08% = 0.92

8. Rev. Trend 61.66% = 4.62

9. EPS Trend -3.15% = -0.16

What is the price of TEVA shares?

As of November 17, 2025, the stock is trading at USD 25.41 with a total of 10,071,100 shares traded.
Over the past week, the price has changed by +4.74%, over one month by +29.44%, over three months by +40.70% and over the past year by +54.09%.

Is Teva Pharma Industries a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Teva Pharma Industries is currently (November 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 52.38 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TEVA is around 28.99 USD . This means that TEVA is currently undervalued and has a potential upside of +14.09% (Margin of Safety).

Is TEVA a buy, sell or hold?

Teva Pharma Industries has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy TEVA.

Strong Buy: 6
Buy: 4
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the TEVA price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	27.7	8.9%
Analysts Target Price	27.7	8.9%
ValueRay Target Price	31.7	24.6%

TEVA Fundamental Data Overview November 15, 2025

Market Cap USD = 30.24b (30.24b USD * 1.0 USD.USD)
P/E Trailing = 41.8689
P/E Forward = 9.0992
P/S = 1.8026
P/B = 4.0875
P/EG = 1.2934
Beta = 0.697
Revenue TTM = 16.78b USD
EBIT TTM = 2.67b USD
EBITDA TTM = 3.69b USD
Long Term Debt = 16.77b USD (from longTermDebt, last quarter)
Short Term Debt = 24.0m USD (from shortTermDebt, last quarter)
Debt = 17.09b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 14.89b USD (from netDebt column, last quarter)
Enterprise Value = 45.13b USD (30.24b + Debt 17.09b - CCE 2.20b)
Interest Coverage Ratio = 1.80 (Ebit TTM 2.67b / Interest Expense TTM 1.49b)
FCF Yield = 1.28% (FCF TTM 578.0m / Enterprise Value 45.13b)
FCF Margin = 3.45% (FCF TTM 578.0m / Revenue TTM 16.78b)
Net Margin = 4.24% (Net Income TTM 712.0m / Revenue TTM 16.78b)
Gross Margin = 50.09% ((Revenue TTM 16.78b - Cost of Revenue TTM 8.37b) / Revenue TTM)
Gross Margin QoQ = 51.43% (prev 50.34%)
Tobins Q-Ratio = 1.13 (Enterprise Value 45.13b / Total Assets 39.86b)
Interest Expense / Debt = 1.22% (Interest Expense 209.0m / Debt 17.09b)
Taxrate = 33.02% (214.0m / 648.0m)
NOPAT = 1.79b (EBIT 2.67b * (1 - 33.02%))
Current Ratio = 1.11 (Total Current Assets 12.74b / Total Current Liabilities 11.49b)
Debt / Equity = 2.36 (Debt 17.09b / totalStockholderEquity, last quarter 7.25b)
Debt / EBITDA = 4.04 (Net Debt 14.89b / EBITDA 3.69b)
Debt / FCF = 25.76 (Net Debt 14.89b / FCF TTM 578.0m)
Total Stockholder Equity = 6.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.79% (Net Income 712.0m / Total Assets 39.86b)
RoE = 11.08% (Net Income TTM 712.0m / Total Stockholder Equity 6.43b)
RoCE = 11.52% (EBIT 2.67b / Capital Employed (Equity 6.43b + L.T.Debt 16.77b))
RoIC = 7.60% (NOPAT 1.79b / Invested Capital 23.54b)
WACC = 6.19% (E(30.24b)/V(47.33b) * Re(9.23%) + D(17.09b)/V(47.33b) * Rd(1.22%) * (1-Tc(0.33)))
Discount Rate = 9.23% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.18%
[DCF Debug] Terminal Value 77.08% ; FCFE base≈1.14b ; Y1≈1.35b ; Y5≈2.11b
Fair Price DCF = 25.40 (DCF Value 29.15b / Shares Outstanding 1.15b; 5y FCF grow 19.98% → 3.0% )
EPS Correlation: -3.15 | EPS CAGR: 3.48% | SUE: 0.28 | # QB: 0
Revenue Correlation: 61.66 | Revenue CAGR: 5.33% | SUE: 0.81 | # QB: 0

Additional Sources for TEVA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle